Neurology
Sangamo Therapeutics and Genentech team up to develop genomic medicines for neurodegenerative diseases
August 7, 2024Research and Development Genentech, Neurology, Sangamo Therapeutics, genomic medicine, neurodegenerative diseases
Genomic medicine company Sangamo Therapeutics and Genentech have entered into a licensing agreement to develop intravenously administered genomic medicines to …
Abbvie acquires Cerevel Therapeutics
August 2, 2024Mergers and Acquisitions AbbVie, Cerevel Therapeutics, Drug-Resistant Epilepsy, Neurology, Parkinson's disease, major depressive disorder, mergers & acquisitions, neurology, neuroscience, schizophrenia
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple programmes across neurological and psychiatric …
Eisai presents latest findings for lecanemab at Alzheimer’s Association International Conference (AAIC)
July 31, 2024Research and Development Alzheimers, Conference results, Eisai, Neurology
Clarity AD open-label extension (OLE) data show: three years of continuous lecanemab treatment reduced clinical decline by -0.95 vs expected …
AC Immune’s pTau-targeting immunotherapy awarded Fast Track designation by FDA
July 26, 2024Research and Development AC Immune, Alzheimer's disease, Neurology, clinical trials, fast track designation, immunotherapy, tau protein
Clinical-stage biopharmaceutical company AC Immune announced that the US Food and Drug Administration (FDA) has granted its Alzheimer’s disease (AD) …
Eisai and EcoNaviSta enter dementia collaboration
July 25, 2024Business Services EcoNaviSta, Eisai, Neurology, collaboration, dementia
Eisai and EcoNaviSta have announced that they have entered into a business alliance agreement, initiating their collaboration intended to build …
J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression
July 24, 2024Medical Communications J&J, Johnson & Johnson, Neurology, Spravato, treatment-resistant depression
Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application (sNDA) to the US Food …
Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment
July 3, 2024Medical Communications Alzheimer's, Eli Lilly, Kisunla, Neurology
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for …
NeuroSense shares update from ALS treatment trial
July 2, 2024Research and Development NeuroSense, Neurology, als, clinical trial
NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study which assessed PrimeC …
Sanofi shares results from phase 2 trial for frexalimab in MS treatment
July 1, 2024Research and Development MS, Neurology, Sanofi, multiple sclerosis
Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for the treatment of patients with …
Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
June 28, 2024Business Services Alzheimers, Biogen, Eisai, Leqembi, Neurology, lecanemab
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment …
AskBio initiates phase 2 Parkinson’s trial recruitment
June 26, 2024Research and Development AskBio, Neurology, Parkinson's disease, clinical trial
Asklepios BioPharmaceutical (AskBio), a subsidiary of Bayer, has announced that it has initiated the recruitment for its phase 2 REGENERATE-PD …
Takeda shares data from phase 3 trial of CIPD treatment
June 20, 2024Research and Development CIDP, Hyqvia, Neurology, Takeda, clinical trial
Takeda has announced data from the phase 3 ADVANCE-CIDP 3 trial, which assessed the safety and efficacy of Hyqvia (Immune …
Cara Therapeutics shares data from part a of notalgia paresthetica trial
June 13, 2024Research and Development Cara Therapeutics, Neurology, clinical trial, notalgia paresthetica, pruritus
Cara Therapeutics has announced the outcome from the dose-finding Part A of the KOURAGE-1 study which assessed the efficacy and …
Evotec shares progress in Bristol Myers Squibb neuroscience collaboration
June 12, 2024Research and Development Evotec, Neurology, bristol myers squibb, neuroscience
Evotec has announced that it has reached important scientific progress within the neuroscience collaboration with Bristol Myers Squibb, initiating a …
FDA accepts Eisai’s Leqembi sBLA for early AD treatment
June 11, 2024Medical Communications Alzheimer's, Biogen, FDA, Neurology, sBLA
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted Eisai’s supplemental biologics license application …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
